Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: A retrospective study

P. Razzore, A. Colao, R. Baldelli, D. Gaia, P. Marzullo, E. Ferretti, D. Ferone, M. L. Jaffrain-Rea, G. Tamburrano, G. Lombardi, F. Camanni, Enrica Ciccarelli

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: We analysed the effects of 6-months' treatment with octreotide s.c. and lanreotide-SR on circulating GH and IGF-I levels in acromegaly. DESIGN: Open retrospective study. PATIENTS: Thirty-eight patients with active acromegaly (plasma IGF-1 levels greater than 2 standard deviations for age-matched controls and increased serum GH levels not suppressible by oral glucose load) were studied. All patients received s.c. octreotide at a dose of 150-600 μg/day for six months as first therapy and subsequently, lanreotide i.m., 30-60 mg either at 14 or 10 day intervals, for 6 months. A 3 months' washout was applied before starting lanreotide treatment. MEASUREMENTS: Mean serum GH levels (from three samples), IGF-1, and clinical examination were performed before and 30, 60, 90 and 180 days after octreotide and lanreotide treatments. Safety tests, HbA1c and, thyroid function were evaluated every three months. RESULTS: Circulating GH and IGF- 1 levels were significantly reduced (P

Original languageEnglish
Pages (from-to)159-164
Number of pages6
JournalClinical Endocrinology
Volume51
Issue number2
DOIs
Publication statusPublished - 1999

ASJC Scopus subject areas

  • Endocrinology

Fingerprint Dive into the research topics of 'Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: A retrospective study'. Together they form a unique fingerprint.

  • Cite this

    Razzore, P., Colao, A., Baldelli, R., Gaia, D., Marzullo, P., Ferretti, E., Ferone, D., Jaffrain-Rea, M. L., Tamburrano, G., Lombardi, G., Camanni, F., & Ciccarelli, E. (1999). Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: A retrospective study. Clinical Endocrinology, 51(2), 159-164. https://doi.org/10.1046/j.1365-2265.1999.00812.x